Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

STUART SHAFER

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1003818816
CMS profile
171
Location
VERO BEACH, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$2,346.32

94 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,151.87 92
Education $194.45 2

By paying entity

PY2023 · entire year · sorted by reported total

Page 2 of 2; records 51–94 of 94 matching records. This page contains 44 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

STUART SHAFER

NPI 1003818816 · CMS profile ID 171

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

VERO BEACH, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–94 of 94 matching records. This page contains 44 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1003818816?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
STUART SHAFER, NPI 1003818816, CMS profile ID 171. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–94 of 94 matching records. This page contains 44 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1003818816?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). STUART SHAFER, NPI 1003818816, CMS profile ID 171. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–94 of 94 matching records. This page contains 44 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1003818816?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
STUART SHAFER, NPI 1003818816, CMS profile ID 171, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–94 of 94 matching records. This page contains 44 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1003818816?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

94 matching records · $2,346.32 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 94 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–94 of 94.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
EMD Serono, Inc. $35.8005/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032343557 CMS
Alnylam Pharmaceuticals Inc. $27.5205/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1006153831 CMS
Novartis Pharmaceuticals Corporation $11.8305/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993257785 CMS
Biogen, Inc. $14.9305/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012202521 CMS
AbbVie Inc. $18.4705/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998923599 CMS
Celgene Corporation $22.3405/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015393859 CMS
Takeda Pharmaceuticals U.S.A., Inc. $33.6405/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055594735 CMS
Sumitomo Pharma America, Inc. $26.3605/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1030768083 CMS
Genentech USA, Inc. $114.5705/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040567889 CMS
Corium, LLC $14.8805/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 978417399 CMS
InSightec,Inc $14.5805/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014517137 CMS
Biogen, Inc. $23.6904/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012196273 CMS
AbbVie Inc. $28.3604/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998923593 CMS
Novartis Pharmaceuticals Corporation $2.4004/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993257775 CMS
Novartis Pharmaceuticals Corporation $11.7804/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993257777 CMS
Lilly USA, LLC $25.2604/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032145291 CMS
Alexion Pharmaceuticals, Inc. $24.2504/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016993715 CMS
Amneal Pharmaceuticals LLC $14.8904/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053534509 CMS
Horizon Therapeutics plc $15.8804/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 987072881 CMS
Biogen, Inc. $59.5803/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012127735 CMS
Novartis Pharmaceuticals Corporation $15.2403/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993257783 CMS
Biogen, Inc. $27.4903/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012257397 CMS
SK Life Science, Inc. $31.9203/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1054807725 CMS
Sumitomo Pharma America, Inc. $15.9603/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1030768085 CMS
Otsuka America Pharmaceutical, Inc. $22.0003/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014802310 CMS
Teva Pharmaceuticals USA, Inc. $22.1003/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056781645 CMS
Genentech USA, Inc. $13.9003/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040567892 CMS
EMD Serono, Inc. $39.0503/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032444009 CMS
Biogen, Inc. $22.9102/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012272539 CMS
AbbVie Inc. $5.8602/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998923587 CMS
Merz Pharmaceuticals, LLC $26.0902/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048303026 CMS
EMD Serono, Inc. $23.2502/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032446689 CMS
Amneal Pharmaceuticals LLC $18.3902/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053534503 CMS
Celgene Corporation $20.8202/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015393779 CMS
Alexion Pharmaceuticals, Inc. $23.4801/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1017075295 CMS
PFIZER INC. $27.5001/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049090907 CMS
Biogen, Inc. $25.0001/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012135763 CMS
EMD Serono, Inc. $24.8201/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032432211 CMS
ARGENX US, INC. $15.0701/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060432103 CMS
Teva Pharmaceuticals USA, Inc. $22.5301/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056781625 CMS
GENZYME CORPORATION $94.9901/05/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049824423 CMS
GENZYME CORPORATION $33.7101/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049824429 CMS
Novartis Pharmaceuticals Corporation $2.5701/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993257779 CMS
Novartis Pharmaceuticals Corporation $21.1801/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993257781 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $56,225.07 131
PY2020 $18,046.50 84
PY2021 $16,356.97 123
PY2022 $10,006.11 110
PY2023 $2,346.32 94
PY2024 $1,945.71 76
PY2025 $3,113.54 105

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $516,634.87 114
PY2024 Principal investigator $581,844.54 71
PY2023 Principal investigator $631,181.77 107
PY2022 Principal investigator $645,256.25 113
PY2021 Principal investigator $848,767.86 210
PY2020 Principal investigator $889,316.35 161
PY2019 Principal investigator $805,393.74 228

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

114 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Hoffmann-La Roche Limited $144.00 12/01/2025 Non-covered Recipient Entity
GEODYSSEY RESEARCH LLC
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211609986
Principal investigator 1 Hoffmann-La Roche Limited $229.00 12/01/2025 Non-covered Recipient Entity
GEODYSSEY RESEARCH LLC
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211609991
Principal investigator 1 Hoffmann-La Roche Limited $85.00 12/01/2025 Non-covered Recipient Entity
GEODYSSEY RESEARCH LLC
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211609994
Principal investigator 1 Novartis Pharmaceuticals Corporation $23,471.61 11/19/2025 Non-covered Recipient Entity
VERO BEACH NEUROLOGY
A Randomized, Open-label, Parallel-group, Non-inferiority Study Comparing Efficacy, Safety, and Tolerability of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis, Followed by Open-label Treatment With R No dispute reported 06/30/2026 1190306555
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $3,290.00 11/12/2025 Non-covered Recipient Entity
Geodyssey Research, Llc
A Multicenter, Longitudinal, Open-Label, Single-Arm Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated with Ozanimod (RPC-1063) No dispute reported 06/30/2026 1235997161
Principal investigator 1 F. Hoffmann-La Roche AG $143.00 11/12/2025 Non-covered Recipient Entity
GEODYSSEY RESEARCH LLC
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211609666
Principal investigator 1 F. Hoffmann-La Roche AG $78.00 11/12/2025 Non-covered Recipient Entity
GEODYSSEY RESEARCH LLC
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211609676
Principal investigator 1 F. Hoffmann-La Roche AG $123.11 11/05/2025 Non-covered Recipient Entity
GEODYSSEY RESEARCH LLC
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211609670
Principal investigator 1 F. Hoffmann-La Roche AG $68.00 11/05/2025 Non-covered Recipient Entity
GEODYSSEY RESEARCH LLC
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211609680
Principal investigator 1 Hoffmann-La Roche Limited $3,799.00 10/28/2025 Non-covered Recipient Entity
GEODYSSEY RESEARCH LLC
Study of ocrelizumab in PPMS patients assessing upper limb function No dispute reported 06/30/2026 1211609971
Principal investigator 1 Roche Products Limited $313.00 10/23/2025 Non-covered Recipient Entity
GEODYSSEY RESEARCH LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211609772
Principal investigator 1 Hoffmann-La Roche Limited $1,625.00 10/21/2025 Non-covered Recipient Entity
GEODYSSEY RESEARCH LLC
Study of ocrelizumab in PPMS patients assessing upper limb function No dispute reported 06/30/2026 1211609977
Principal investigator 1 Hoffmann-La Roche Limited $100.00 10/16/2025 Non-covered Recipient Entity
GEODYSSEY RESEARCH LLC
Study of ocrelizumab in PPMS patients assessing upper limb function No dispute reported 06/30/2026 1211609967
Principal investigator 1 Hoffmann-La Roche Limited $100.00 10/16/2025 Non-covered Recipient Entity
GEODYSSEY RESEARCH LLC
Study of ocrelizumab in PPMS patients assessing upper limb function No dispute reported 06/30/2026 1211609975
Principal investigator 1 Hoffmann-La Roche Limited $45.50 10/16/2025 Non-covered Recipient Entity
GEODYSSEY RESEARCH LLC
Study of ocrelizumab in PPMS patients assessing upper limb function No dispute reported 06/30/2026 1211609982
Principal investigator 1 Roche Products Limited $237.40 10/16/2025 Non-covered Recipient Entity
GEODYSSEY RESEARCH LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211609777
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,107.73 10/08/2025 Non-covered Recipient Entity
MS CENTER OF VERO BEACH
A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib No dispute reported 06/30/2026 1190302855
Principal investigator 1 F. Hoffmann-La Roche AG $98.00 10/02/2025 Non-covered Recipient Entity
GEODYSSEY RESEARCH LLC
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211609636
Principal investigator 1 F. Hoffmann-La Roche AG $30.00 10/02/2025 Non-covered Recipient Entity
GEODYSSEY RESEARCH LLC
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211609641
Principal investigator 1 F. Hoffmann-La Roche AG $46.00 10/02/2025 Non-covered Recipient Entity
GEODYSSEY RESEARCH LLC
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211609646
Principal investigator 1 F. Hoffmann-La Roche AG $46.00 10/02/2025 Non-covered Recipient Entity
GEODYSSEY RESEARCH LLC
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211609650
Principal investigator 1 F. Hoffmann-La Roche AG $30.00 10/02/2025 Non-covered Recipient Entity
GEODYSSEY RESEARCH LLC
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211609654
Principal investigator 1 F. Hoffmann-La Roche AG $450.00 10/02/2025 Non-covered Recipient Entity
GEODYSSEY RESEARCH LLC
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211609658
Principal investigator 1 F. Hoffmann-La Roche AG $95.97 10/02/2025 Non-covered Recipient Entity
GEODYSSEY RESEARCH LLC
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211609662
Principal investigator 1 F. Hoffmann-La Roche AG $837.00 09/22/2025 Non-covered Recipient Entity
GEODYSSEY RESEARCH LLC
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211609627
Principal investigator 1 Hoffmann-La Roche Limited $611.00 09/16/2025 Non-covered Recipient Entity
GEODYSSEY RESEARCH LLC
Study of ocrelizumab in PPMS patients assessing upper limb function No dispute reported 06/30/2026 1211609955
Principal investigator 1 F. Hoffmann-La Roche AG $1,250.00 09/15/2025 Non-covered Recipient Entity
GEODYSSEY RESEARCH LLC
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211609616
Principal investigator 1 F. Hoffmann-La Roche AG $7,764.00 09/15/2025 Non-covered Recipient Entity
GEODYSSEY RESEARCH LLC
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211609620
Principal investigator 1 F. Hoffmann-La Roche AG $7,764.00 09/15/2025 Non-covered Recipient Entity
GEODYSSEY RESEARCH LLC
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211609623
Principal investigator 1 Hoffmann-La Roche Limited $1,625.00 08/21/2025 Non-covered Recipient Entity
GEODYSSEY RESEARCH LLC
Study of ocrelizumab in PPMS patients assessing upper limb function No dispute reported 06/30/2026 1211609963
Principal investigator 1 Roche Products Limited $313.00 08/21/2025 Non-covered Recipient Entity
GEODYSSEY RESEARCH LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211609733
Principal investigator 1 Roche Products Limited $300.00 08/21/2025 Non-covered Recipient Entity
GEODYSSEY RESEARCH LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211609763
Principal investigator 1 Hoffmann-La Roche Limited $520.00 08/01/2025 Non-covered Recipient Entity
GEODYSSEY RESEARCH LLC
Study of ocrelizumab in PPMS patients assessing upper limb function No dispute reported 06/30/2026 1211609950
Principal investigator 1 Hoffmann-La Roche Limited $585.00 08/01/2025 Non-covered Recipient Entity
GEODYSSEY RESEARCH LLC
Study of ocrelizumab in PPMS patients assessing upper limb function No dispute reported 06/30/2026 1211609959
Principal investigator 1 Roche Products Limited $313.00 07/24/2025 Non-covered Recipient Entity
GEODYSSEY RESEARCH LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211609726
Principal investigator 1 Roche Products Limited $313.00 07/24/2025 Non-covered Recipient Entity
GEODYSSEY RESEARCH LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211609729
Principal investigator 1 Roche Products Limited $313.00 07/24/2025 Non-covered Recipient Entity
GEODYSSEY RESEARCH LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211609737
Principal investigator 1 Roche Products Limited $313.00 07/24/2025 Non-covered Recipient Entity
GEODYSSEY RESEARCH LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211609741
Principal investigator 1 Roche Products Limited $313.00 07/24/2025 Non-covered Recipient Entity
GEODYSSEY RESEARCH LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211609744
Principal investigator 1 Roche Products Limited $313.00 07/24/2025 Non-covered Recipient Entity
GEODYSSEY RESEARCH LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211609748
Principal investigator 1 Roche Products Limited $313.00 07/24/2025 Non-covered Recipient Entity
GEODYSSEY RESEARCH LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211609756
Principal investigator 1 Roche Products Limited $313.00 07/24/2025 Non-covered Recipient Entity
GEODYSSEY RESEARCH LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211609760
Principal investigator 1 F. Hoffmann-La Roche AG $837.00 07/23/2025 Non-covered Recipient Entity
GEODYSSEY RESEARCH LLC
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211609632
Principal investigator 1 Roche Products Limited $600.00 07/03/2025 Non-covered Recipient Entity
GEODYSSEY RESEARCH LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211609753
Principal investigator 1 Roche Products Limited $313.00 07/03/2025 Non-covered Recipient Entity
GEODYSSEY RESEARCH LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211609767
Principal investigator 1 Roche Products Limited $313.00 06/19/2025 Non-covered Recipient Entity
GEODYSSEY RESEARCH LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211609687
Principal investigator 1 Roche Products Limited $313.00 06/19/2025 Non-covered Recipient Entity
GEODYSSEY RESEARCH LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211609692
Principal investigator 1 Roche Products Limited $313.00 06/19/2025 Non-covered Recipient Entity
GEODYSSEY RESEARCH LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211609698
Principal investigator 1 Roche Products Limited $313.00 06/19/2025 Non-covered Recipient Entity
GEODYSSEY RESEARCH LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211609702
Principal investigator 1 Roche Products Limited $313.00 06/19/2025 Non-covered Recipient Entity
GEODYSSEY RESEARCH LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211609717
Principal investigator 1 Roche Products Limited $313.00 06/19/2025 Non-covered Recipient Entity
GEODYSSEY RESEARCH LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211609721
Principal investigator 1 F. Hoffmann-La Roche AG $299.00 05/27/2025 Non-covered Recipient Entity
GEODYSSEY RESEARCH LLC
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211609605
Principal investigator 1 F. Hoffmann-La Roche AG $299.00 05/27/2025 Non-covered Recipient Entity
GEODYSSEY RESEARCH LLC
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211609609
Principal investigator 1 F. Hoffmann-La Roche AG $30.00 05/27/2025 Non-covered Recipient Entity
GEODYSSEY RESEARCH LLC
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211609612
Principal investigator 1 Roche Products Limited $313.00 05/22/2025 Non-covered Recipient Entity
GEODYSSEY RESEARCH LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211609713
Principal investigator 1 Hoffmann-La Roche Limited $397.00 05/20/2025 Non-covered Recipient Entity
GEODYSSEY RESEARCH LLC
Study of ocrelizumab in PPMS patients assessing upper limb function No dispute reported 06/30/2026 1211609923
Principal investigator 1 Novartis Pharmaceuticals Corporation $22,142.00 05/13/2025 Non-covered Recipient Entity
GEODYSSEY RESEARCH, LLC
A Randomized, Open Label, Multi-center, Active-comparator Study to Assess Efficacy, Safety & Tolerability of Ofatumumab 20mg sc Monthly Versus Continued Current Therapy in Relapsing-remitting Multiple Sclerosis After Elevation of Serum Neurofilament Light No dispute reported 06/30/2026 1190299649
Principal investigator 1 Hoffmann-La Roche Limited $1,338.30 05/08/2025 Non-covered Recipient Entity
GEODYSSEY RESEARCH LLC
Study of ocrelizumab in PPMS patients assessing upper limb function No dispute reported 06/30/2026 1211609927
Principal investigator 1 Roche Products Limited $313.00 05/08/2025 Non-covered Recipient Entity
GEODYSSEY RESEARCH LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211609707
Principal investigator 1 Hoffmann-La Roche Limited $1,625.00 05/01/2025 Non-covered Recipient Entity
GEODYSSEY RESEARCH LLC
Study of ocrelizumab in PPMS patients assessing upper limb function No dispute reported 06/30/2026 1211609932
Principal investigator 1 Hoffmann-La Roche Limited $7,659.90 04/24/2025 Non-covered Recipient Entity
GEODYSSEY RESEARCH LLC
Study of ocrelizumab in PPMS patients assessing upper limb function No dispute reported 06/30/2026 1211609919
Principal investigator 1 Hoffmann-La Roche Limited $2,792.00 04/24/2025 Non-covered Recipient Entity
GEODYSSEY RESEARCH LLC
Study of ocrelizumab in PPMS patients assessing upper limb function No dispute reported 06/30/2026 1211609936
Principal investigator 1 Hoffmann-La Roche Limited $74.62 04/17/2025 Non-covered Recipient Entity
GEODYSSEY RESEARCH LLC
Study of ocrelizumab in PPMS patients assessing upper limb function No dispute reported 06/30/2026 1211609941
Principal investigator 1 Hoffmann-La Roche Limited $780.00 04/17/2025 Non-covered Recipient Entity
GEODYSSEY RESEARCH LLC
Study of ocrelizumab in PPMS patients assessing upper limb function No dispute reported 06/30/2026 1211609945
Principal investigator 1 F. Hoffmann-La Roche AG $500.00 03/12/2025 Non-covered Recipient Entity
GEODYSSEY RESEARCH LLC
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211609568
Principal investigator 1 F. Hoffmann-La Roche AG $1,250.00 03/12/2025 Non-covered Recipient Entity
GEODYSSEY RESEARCH LLC
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211609571
Principal investigator 1 F. Hoffmann-La Roche AG $84.99 03/12/2025 Non-covered Recipient Entity
GEODYSSEY RESEARCH LLC
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211609584
Principal investigator 1 F. Hoffmann-La Roche AG $68.00 03/12/2025 Non-covered Recipient Entity
GEODYSSEY RESEARCH LLC
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211609588
Principal investigator 1 F. Hoffmann-La Roche AG $1,250.00 03/12/2025 Non-covered Recipient Entity
GEODYSSEY RESEARCH LLC
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211609592
Principal investigator 1 F. Hoffmann-La Roche AG $30.00 03/12/2025 Non-covered Recipient Entity
GEODYSSEY RESEARCH LLC
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211609596
Principal investigator 1 Hoffmann-La Roche Limited $26.00 03/06/2025 Non-covered Recipient Entity
GEODYSSEY RESEARCH LLC
Study of ocrelizumab in PPMS patients assessing upper limb function No dispute reported 06/30/2026 1211609793
Principal investigator 1 Hoffmann-La Roche Limited $324.00 03/06/2025 Non-covered Recipient Entity
GEODYSSEY RESEARCH LLC
Study of ocrelizumab in PPMS patients assessing upper limb function No dispute reported 06/30/2026 1211609823
Principal investigator 1 Hoffmann-La Roche Limited $40.50 03/06/2025 Non-covered Recipient Entity
GEODYSSEY RESEARCH LLC
Study of ocrelizumab in PPMS patients assessing upper limb function No dispute reported 06/30/2026 1211609865
Principal investigator 1 Celgene Corporation $16,431.60 02/28/2025 Non-covered Recipient Entity
Geodyssey Research, Llc
A Multicenter, Longitudinal, Open-Label, Single-Arm Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated with Ozanimod (RPC-1063) No dispute reported 06/30/2026 1222306931
Principal investigator 1 Hoffmann-La Roche Limited $736.00 02/25/2025 Non-covered Recipient Entity
GEODYSSEY RESEARCH LLC
Study of ocrelizumab in PPMS patients assessing upper limb function No dispute reported 06/30/2026 1211609892
Principal investigator 1 Hoffmann-La Roche Limited $384.00 02/20/2025 Non-covered Recipient Entity
GEODYSSEY RESEARCH LLC
Study of ocrelizumab in PPMS patients assessing upper limb function No dispute reported 06/30/2026 1211609797
Principal investigator 1 Hoffmann-La Roche Limited $508.00 02/20/2025 Non-covered Recipient Entity
GEODYSSEY RESEARCH LLC
Study of ocrelizumab in PPMS patients assessing upper limb function No dispute reported 06/30/2026 1211609809
Principal investigator 1 Hoffmann-La Roche Limited $1,191.00 02/20/2025 Non-covered Recipient Entity
GEODYSSEY RESEARCH LLC
Study of ocrelizumab in PPMS patients assessing upper limb function No dispute reported 06/30/2026 1211609817
Principal investigator 1 Hoffmann-La Roche Limited $604.00 02/20/2025 Non-covered Recipient Entity
GEODYSSEY RESEARCH LLC
Study of ocrelizumab in PPMS patients assessing upper limb function No dispute reported 06/30/2026 1211609846
Principal investigator 1 Hoffmann-La Roche Limited $456.00 02/20/2025 Non-covered Recipient Entity
GEODYSSEY RESEARCH LLC
Study of ocrelizumab in PPMS patients assessing upper limb function No dispute reported 06/30/2026 1211609869
Principal investigator 1 Hoffmann-La Roche Limited $294.00 02/20/2025 Non-covered Recipient Entity
GEODYSSEY RESEARCH LLC
Study of ocrelizumab in PPMS patients assessing upper limb function No dispute reported 06/30/2026 1211609888
Principal investigator 1 F. Hoffmann-La Roche AG $3,288.00 02/19/2025 Non-covered Recipient Entity
GEODYSSEY RESEARCH LLC
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211609576
Principal investigator 1 F. Hoffmann-La Roche AG $3,288.00 02/19/2025 Non-covered Recipient Entity
GEODYSSEY RESEARCH LLC
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211609580
Principal investigator 1 Hoffmann-La Roche Limited $144.00 02/13/2025 Non-covered Recipient Entity
GEODYSSEY RESEARCH LLC
Study of ocrelizumab in PPMS patients assessing upper limb function No dispute reported 06/30/2026 1211609800
Principal investigator 1 Hoffmann-La Roche Limited $736.00 02/13/2025 Non-covered Recipient Entity
GEODYSSEY RESEARCH LLC
Study of ocrelizumab in PPMS patients assessing upper limb function No dispute reported 06/30/2026 1211609831
Principal investigator 1 Hoffmann-La Roche Limited $3,799.00 02/13/2025 Non-covered Recipient Entity
GEODYSSEY RESEARCH LLC
Study of ocrelizumab in PPMS patients assessing upper limb function No dispute reported 06/30/2026 1211609854
Principal investigator 1 Hoffmann-La Roche Limited $45.50 02/11/2025 Non-covered Recipient Entity
GEODYSSEY RESEARCH LLC
Study of ocrelizumab in PPMS patients assessing upper limb function No dispute reported 06/30/2026 1211609835
Principal investigator 1 Hoffmann-La Roche Limited $585.00 02/11/2025 Non-covered Recipient Entity
GEODYSSEY RESEARCH LLC
Study of ocrelizumab in PPMS patients assessing upper limb function No dispute reported 06/30/2026 1211609884
Principal investigator 1 Hoffmann-La Roche Limited $585.00 02/11/2025 Non-covered Recipient Entity
GEODYSSEY RESEARCH LLC
Study of ocrelizumab in PPMS patients assessing upper limb function No dispute reported 06/30/2026 1211609896
Principal investigator 1 Hoffmann-La Roche Limited $100.00 02/06/2025 Non-covered Recipient Entity
GEODYSSEY RESEARCH LLC
Study of ocrelizumab in PPMS patients assessing upper limb function No dispute reported 06/30/2026 1211609781
Principal investigator 1 Hoffmann-La Roche Limited $1,625.00 02/06/2025 Non-covered Recipient Entity
GEODYSSEY RESEARCH LLC
Study of ocrelizumab in PPMS patients assessing upper limb function No dispute reported 06/30/2026 1211609850
Principal investigator 1 Hoffmann-La Roche Limited $1,625.00 02/06/2025 Non-covered Recipient Entity
GEODYSSEY RESEARCH LLC
Study of ocrelizumab in PPMS patients assessing upper limb function No dispute reported 06/30/2026 1211609881
Principal investigator 1 Hoffmann-La Roche Limited $85.00 02/06/2025 Non-covered Recipient Entity
GEODYSSEY RESEARCH LLC
Study of ocrelizumab in PPMS patients assessing upper limb function No dispute reported 06/30/2026 1211609915
Principal investigator 1 UCB SA $4,300.00 02/06/2025 Non-covered Recipient Entity
Geodyssey Research, Llc
A MULTICENTER PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF UCB0022 IN STUDY PARTICIPANTS WITH ADVANCED Parkinsons DISEASE No dispute reported 06/30/2026 1246657732
Principal investigator 1 Hoffmann-La Roche Limited $59.46 02/04/2025 Non-covered Recipient Entity
GEODYSSEY RESEARCH LLC
Study of ocrelizumab in PPMS patients assessing upper limb function No dispute reported 06/30/2026 1211609789
Principal investigator 1 Hoffmann-La Roche Limited $83.25 02/04/2025 Non-covered Recipient Entity
GEODYSSEY RESEARCH LLC
Study of ocrelizumab in PPMS patients assessing upper limb function No dispute reported 06/30/2026 1211609827
Principal investigator 1 Hoffmann-La Roche Limited $82.02 02/04/2025 Non-covered Recipient Entity
GEODYSSEY RESEARCH LLC
Study of ocrelizumab in PPMS patients assessing upper limb function No dispute reported 06/30/2026 1211609904
Principal investigator 1 Hoffmann-La Roche Limited $100.00 02/04/2025 Non-covered Recipient Entity
GEODYSSEY RESEARCH LLC
Study of ocrelizumab in PPMS patients assessing upper limb function No dispute reported 06/30/2026 1211609909
Principal investigator 1 Novartis Pharmaceuticals Corporation $93,752.83 01/31/2025 Non-covered Recipient Entity
VERO BEACH NEUROLOGY
A Randomized, Open Label, Multi-center, Active-comparator Study to Assess Efficacy, Safety & Tolerability of Ofatumumab 20mg sc Monthly Versus Continued Current Therapy in Relapsing-remitting Multiple Sclerosis After Elevation of Serum Neurofilament Light No dispute reported 06/30/2026 1190306557
Principal investigator 1 Hoffmann-La Roche Limited $3,510.00 01/23/2025 Non-covered Recipient Entity
GEODYSSEY RESEARCH LLC
Study of ocrelizumab in PPMS patients assessing upper limb function No dispute reported 06/30/2026 1211609805
Principal investigator 1 Hoffmann-La Roche Limited $144.00 01/23/2025 Non-covered Recipient Entity
GEODYSSEY RESEARCH LLC
Study of ocrelizumab in PPMS patients assessing upper limb function No dispute reported 06/30/2026 1211609813
Principal investigator 1 Hoffmann-La Roche Limited $1,625.00 01/23/2025 Non-covered Recipient Entity
GEODYSSEY RESEARCH LLC
Study of ocrelizumab in PPMS patients assessing upper limb function No dispute reported 06/30/2026 1211609839
Principal investigator 1 Roche Products Limited $313.00 01/23/2025 Non-covered Recipient Entity
GEODYSSEY RESEARCH LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211609683
Principal investigator 1 F. Hoffmann-La Roche AG $837.00 01/22/2025 Non-covered Recipient Entity
GEODYSSEY RESEARCH LLC
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211609600
Principal investigator 1 Hoffmann-La Roche Limited $59.55 01/21/2025 Non-covered Recipient Entity
GEODYSSEY RESEARCH LLC
Study of ocrelizumab in PPMS patients assessing upper limb function No dispute reported 06/30/2026 1211609786
Principal investigator 1 Hoffmann-La Roche Limited $100.00 01/21/2025 Non-covered Recipient Entity
GEODYSSEY RESEARCH LLC
Study of ocrelizumab in PPMS patients assessing upper limb function No dispute reported 06/30/2026 1211609843
Principal investigator 1 Hoffmann-La Roche Limited $100.00 01/21/2025 Non-covered Recipient Entity
GEODYSSEY RESEARCH LLC
Study of ocrelizumab in PPMS patients assessing upper limb function No dispute reported 06/30/2026 1211609873
Principal investigator 1 Hoffmann-La Roche Limited $100.00 01/21/2025 Non-covered Recipient Entity
GEODYSSEY RESEARCH LLC
Study of ocrelizumab in PPMS patients assessing upper limb function No dispute reported 06/30/2026 1211609877
Principal investigator 1 Hoffmann-La Roche Limited $98.00 01/21/2025 Non-covered Recipient Entity
GEODYSSEY RESEARCH LLC
Study of ocrelizumab in PPMS patients assessing upper limb function No dispute reported 06/30/2026 1211609900
Principal investigator 1 Hoffmann-La Roche Limited $100.00 01/21/2025 Non-covered Recipient Entity
GEODYSSEY RESEARCH LLC
Study of ocrelizumab in PPMS patients assessing upper limb function No dispute reported 06/30/2026 1211609913
Principal investigator 1 Novartis Pharmaceuticals Corporation $36,826.08 01/16/2025 Non-covered Recipient Entity
GEODYSSEY RESEARCH, LLC
A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib No dispute reported 06/30/2026 1190299645
Principal investigator 1 Hoffmann-La Roche Limited $98.00 01/14/2025 Non-covered Recipient Entity
GEODYSSEY RESEARCH LLC
Study of ocrelizumab in PPMS patients assessing upper limb function No dispute reported 06/30/2026 1211609857
Principal investigator 1 Hoffmann-La Roche Limited $100.00 01/09/2025 Non-covered Recipient Entity
GEODYSSEY RESEARCH LLC
Study of ocrelizumab in PPMS patients assessing upper limb function No dispute reported 06/30/2026 1211609861
Principal investigator 1 Novartis Pharmaceuticals Corporation $232,643.95 01/09/2025 Non-covered Recipient Entity
MS CENTER OF VERO BEACH
A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib No dispute reported 06/30/2026 1190302857

Ownership and Investment Interests

One row per program year and measure, newest year first · the amount invested and the value of the interest are never added together

Program yearMeasureAmountRecords
PY2025 Amount invested $74,440.01 2
PY2025 Value of interest $0.01 2
PY2024 Amount invested $0.01 1
PY2024 Value of interest $0.01 1
PY2023 Amount invested $0.00 1
PY2023 Value of interest $0.01 1
PY2020 Amount invested $6,244.00 1
PY2020 Value of interest $0.00 1

Ownership and Investment Interests are a separate CMS dataset, shown here separately and never added to payments.

Ownership and investment interests are reported as the value of an interest held, not as a payment received. They are a different measure from the payment total on this page and are never combined with it.

Ownership and Investment Interests records

Ordering applied by this site (program year, newest first, then company) · record values are shown as CMS published them

5 records · PY2020–2025

Ownership and Investment Interests records (CSV)

Program yearCompanyAmount invested Value of interestTerms of interestInterest held by Dispute statusPublishedRecord ID
PY2025 SWAN VALLEY MEDICAL INCORPORATED $0.01 $0.01 These shares were purchased or granted in past years. This is only to update the value of ownership, which is currently zero. The company is privately held with no public market for the sale of shares so as we stand at the end of 2025, the shares the doctors own are without value. Physician Covered Recipient No dispute reported 06/30/2026 1206074228
PY2025 SWAN VALLEY MEDICAL INCORPORATED $74,440.00 $0.00 N/A Physician Covered Recipient No dispute reported 06/30/2026 1206088043
PY2024 SWAN VALLEY MEDICAL INCORPORATED $0.01 $0.01 These shares were purchased or granted in past years. This is only to update the value of ownership, which is currently zero. The company is privately held with no public market for the sale of shares so as we stand at the end of 2024, the shares the doctors own are without value. Physician Covered Recipient No dispute reported 06/30/2026 1126843863
PY2023 SWAN VALLEY MEDICAL INCORPORATED $0.00 $0.01 Shares listed were purchased or granted for services in past reported years. The current value of these shares is the par value of $0.01. The Company is a privately held C Corporation with no public market for the sale of its highly restricted stock. The Company is has never been profitable and its liabilities currently exceed its assets, with operating expenses exceeding its sales revenues. Physician Covered Recipient No dispute reported 06/30/2026 984209047
PY2020 SWAN VALLEY MEDICAL INCORPORATED $6,244.00 $0.00 N/A Physician Covered Recipient No dispute reported 06/30/2026 739633983